Watanuki Akira, Ohwada Susumu, Fukusato Toshio, Makita Fujio, Yamada Tatsuya, Kikuchi Akihiro, Morishita Yasuo
The Second Department of Surgery, Gunma University Faculty of Medicine, Maebashi, Japan.
Anticancer Res. 2002 Mar-Apr;22(2B):1113-9.
The biological significance of the nuclear enzyme DNA topoisomerase II in hepatocellular carcinoma (HCC) remains unclear.
Using immunohistochemical staining methods, we examined the clinical significance of topo IIalpha (8D2) in surgically resected HCC, comparing the expression of both Ki-67 and p53, as well as various clinicopathological factors and prognosis.
The 70 HCC samples showed a positive, but heterogeneous pattern. The mean topo IIalpha labeling index (LI) was 14.1 +/- 15.1%, and ranged from 0.2 to 55.6, and the median topo IIalpha LI was 9.9%. The mean value of the topo IIalpha LI in p53-positive HCC cases (25.6 +/- 17.4) was significantly higher than that in p53-negative cases (10.3 +/- 12.3). HCC patients with lower topo IIalpha LI had significantly longer disease-free survival and exhibited a longer cumulative survival period than did those with higher topo lIalpha LI.
Topo IIalpha over-expression appears to be linked with a potentially aggressive tumor phenotype and may indicate tumor recurrence and cancer-related death in HCC.
核酶DNA拓扑异构酶II在肝细胞癌（HCC）中的生物学意义尚不清楚。
采用免疫组织化学染色方法，我们检测了拓扑异构酶IIα（8D2）在手术切除的HCC中的临床意义，比较了Ki-67和p53的表达，以及各种临床病理因素和预后情况。
70例HCC样本呈现阳性但不均匀的模式。拓扑异构酶IIα标记指数（LI）的平均值为14.1±15.1%，范围为0.2至55.6，拓扑异构酶IIα LI的中位数为9.9%。p53阳性HCC病例中拓扑异构酶IIα LI的平均值（25.6±17.4）显著高于p53阴性病例（10.3±12.3）。拓扑异构酶IIα LI较低的HCC患者无病生存期明显更长，累积生存期也比拓扑异构酶IIα LI较高的患者更长。
拓扑异构酶IIα的过度表达似乎与潜在的侵袭性肿瘤表型有关，可能预示着HCC中的肿瘤复发和癌症相关死亡。
